Elicio Therapeutics grants director 21,750 options
Elicio Therapeutics granted a time-based annual stock option award to a non-employee director, vesting by 2027 and replacing any 2026 meeting grant.
Rhea-AI Filing Summary
Elicio Therapeutics, Inc. (ELTX) reported that director Allen Nissenson received a stock option award for 21,750 shares of common stock on August 31, 2026. The option has an exercise price of $2.70 per share and expires on August 31, 2036.
The option represents the annual non-employee director equity award and will vest in full on the earlier of August 31, 2027, or the company’s 2027 annual meeting of stockholders, provided he continues to provide services through the vesting date. No additional equity award will be made to him in connection with the 2026 annual meeting of stockholders, and no Rule 10b5-1 trading plan is reported.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 21,750 shares
Grant/Award
1 txn
Insider
Nissenson Allen
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 21,750 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 21,750 contracts (Direct)
Footnotes (1)
- F1. The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders.
Key Figures
Option shares granted: 21,750 shares
Exercise price: $2.70 per share
Expiration date: August 31, 2036
+2 more
5 metrics
Option shares granted
21,750 shares
Stock option representing the annual non-employee director equity award to Allen Nissenson on August 31, 2026
Exercise price
$2.70 per share
Exercise price of the stock option for 21,750 shares granted to Allen Nissenson
Expiration date
August 31, 2036
Expiration of the director stock option for 21,750 shares
Service-based vesting date
Earlier of August 31, 2027 or 2027 annual meeting
Option vests and becomes exercisable in full on the earlier of these dates, subject to continued service
Shares underlying the option after grant
21,750 shares
Total number of option shares held by Allen Nissenson following this reported transaction
Key Terms
annual non-employee director equity award, vest and become exercisable in full, exercise price, expiration date
4 terms
annual non-employee director equity award financial
"The stock option represents the annual non-employee director equity award to the Reporting Person"
vest and become exercisable in full financial
"and shall vest and become exercisable in full on the earlier of (A) August 31, 2027"
exercise price financial
"The stock option has an exercise price of $2.70 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"and expires on August 31, 2036 under the option’s expiration date"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What equity award did director Allen Nissenson receive from ELTX on August 31, 2026?
He received a stock option for 21,750 shares of Elicio Therapeutics common stock, representing the annual non-employee director equity award granted on August 31, 2026, with service-based vesting conditions.
What is the exercise price of Allen Nissenson’s new ELTX stock option?
The stock option has an exercise price of $2.70 per share. It entitles him to buy up to 21,750 shares of Elicio Therapeutics common stock at this price once the option becomes fully vested and exercisable.
When does Allen Nissenson’s ELTX director stock option vest?
The option will vest and become exercisable in full on the earlier of August 31, 2027 or the annual meeting of Elicio Therapeutics’ stockholders held in 2027, subject to him continuing to provide services to the company through that vesting date.
When does Allen Nissenson’s ELTX stock option expire?
The stock option expires on August 31, 2036. After that date, any unexercised portion of the 21,750-share option will no longer be exercisable under the terms disclosed by Elicio Therapeutics.
Will Allen Nissenson receive another equity award at ELTX’s 2026 annual meeting?
No. The company states that no additional equity award will be made to Allen Nissenson in connection with the 2026 annual meeting of stockholders. The reported stock option constitutes his annual non-employee director equity award.
Was Allen Nissenson’s ELTX option grant made under a Rule 10b5-1 trading plan?
No. The filing indicates that no Rule 10b5-1 trading plan is reported in connection with this director stock option grant on August 31, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
